Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

Ladoire, Sylvain, Mignot, Grégoire, Dabakuyo, Sandrine, Arnould, Laurent, Apetoh, Lionel, Rébé, Cedric, Coudert, Bruno, Martin, Francois, Bizollon, Marie Hélène, Vanoli, André, Coutant, Charles, Fumoleau, Pierre, Bonnetain, Franck, Ghiringhelli, François·2011·The Journal of Pathology

Abstract

Accumulating preclinical evidence suggests that anticancer immune responses contribute to the success of chemotherapy. However, the predictive value of tumour‐infiltrating lymphocytes after neoadjuvant chemotherapy for breast cancer remains unknown. We hypothesized that the nature of the immune infiltrate following neoadjuvant chemotherapy would predict patient survival. In a series of 111 consecutive HER2‐ and a series of 51 non‐HER2‐overexpressing breast cancer patients treated by neoadjuvant chemotherapy, we studied by immunohistochemistry tumour infiltration by FOXP3 and CD8 T lymphocytes before and after chemotherapy. Kaplan‐Meier analysis and Cox modelling were used to assess relapse‐free survival (RFS) and overall survival (OS). A predictive scoring system using American Joint Committee on Cancer (AJCC) pathological staging and immunological markers was created. Association of high CD8 and low FOXP3 cell infiltrates after chemotherapy was significantly associated with improved RFS (p = 0.02) and OS (p = 0.002), and outperformed classical predictive factors in multivariate analysis. A combined score associating CD8/FOXP3 ratio and pathological AJCC staging isolated a subgroup of patients with a long‐term overall survival of 100%. Importantly, this score also identified patients with a favourable prognosis in an independent cohort of HER2‐negative breast cancer patients. These results suggest that immunological CD8 and FOXP3 cell infiltrate after treatment is an independent predictive factor of survival in breast cancer patients treated with neoadjuvant chemotherapy and provides new insights into the role of the immune milieu and cancer. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.2866

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 226

Metadata

Authors
Ladoire, S., Mignot, G., Dabakuyo, S., Arnould, L., Apetoh, L., Rébé, C., Coudert, B., Martin, F., Bizollon, M. H., Vanoli, A., Coutant, C., Fumoleau, P., Bonnetain, F., & Ghiringhelli, F.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2011-03-25
Volume
224
Issue
3
Pages
389-400
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W2017999136
Cited by
226
References
10
FWCI
6.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. https://app.cochat.ai/papers/10.1002/path.2866
The paper
Ladoire, S., Mignot, G., Dabakuyo, S., Arnould, L., Apetoh, L., Rébé, C., Coudert, B., Martin, F., Bizollon, M. H., Vanoli, A., Coutant, C., Fumoleau, P., Bonnetain, F., & Ghiringhelli, F. (2011). In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. The Journal of Pathology. https://doi.org/10.1002/path.2866

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.